(Q33607514)

28 July 2017

title

Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial (English)

1 reference

28 July 2017

1 reference

1 reference

J Grossman

1

1 reference

28 July 2017

L J Smith

series ordinal

2

1 reference

28 July 2017

A M Wilson

series ordinal

3

1 reference

28 July 2017

P T Thyrum

series ordinal

4

1 reference

28 July 2017

publication date

1 April 1999

1 reference

Annals of Allergy, Asthma & Immunology

28 July 2017

published in

1 reference

28 July 2017

volume

82

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

361-369

1 reference

Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Worldwide clinical experience with the first marketed leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Issues in patient compliance

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

Nonadherence in asthmatic patients: is there a solution to the problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963285-1

7 January 2021

10.1016/S1081-1206(10)63285-1

Identifiers

DOI

1 reference

28 July 2017

1 reference